替代性降LDL策略与高强度他汀在ASCVD患者中的比较:系统综述与个体患者数据荟萃分析
该系统综述与个体患者数据荟萃分析纳入RACING和LODESTAR两项随机临床试验共8180例ASCVD患者,比较替代性降LDL策略与高强度他汀策略。结果显示两组3年主要终点(全因死亡、心梗、卒中或冠脉血运重建)无差异(7.5% vs 7.7%;HR 0.98;95%CI 0.84-1.15;
要点
- 替代性降LDL策略(中等强度他汀联合依折麦布或达标治疗)与高强度他汀策略3年心血管事件风险相当。
- 替代策略组新发糖尿病及不耐受相关停药或减量发生率更低。
核心结论
- 在ASCVD患者中,替代性降LDL策略与高强度他汀策略相比,3年死亡或心血管事件疗效相当,且LDL-C更低、新发糖尿病和不耐受风险更低。
研究设计与样本
- 系统综述与个体患者数据荟萃分析,纳入RACING和LODESTAR两项随机临床试验,共8180例ASCVD患者(平均年龄64.5岁,女性26.7%)。
- 替代策略定义为RACING中的中等强度他汀联合依折麦布治疗和LODESTAR中的达标治疗策略。
- 主要分析采用一阶段法,主要终点为3年全因死亡、心肌梗死、卒中或冠状动脉血运重建的复合终点。
临床怎么用
- 对于ASCVD患者,可考虑采用中等强度他汀联合依折麦布或达标治疗策略作为高强度他汀的替代方案,尤其关注他汀不耐受或糖尿病风险者。
局限性
- 仅纳入RACING和LODESTAR两项试验的个体患者数据,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In patients with atherosclerotic cardiovascular disease (ASCVD), intensive lowering of low-density lipoprotein (LDL) cholesterol levels with high-intensity statins is generally recommended. However, alternative approaches considering statin-related adverse effects and intolerance are needed. OBJECTIVE: To compare the long-term efficacy and safety of an alternative LDL cholesterol-lowering strategy vs high-intensity statin strategy in patients with ASCVD in randomized clinical trials. DATA SOURCES: PubMed, Embase, and other websites (ClinicalTrials.gov, European Society of Cardiology, tctMD) were systematically searched from inception to April 19, 2024. STUDY SELECTION: Randomized clinical trials comparing an alternative LDL cholesterol-lowering strategy vs a high-intensity statin strategy in patients with ASCVD, with presence of cardiovascular events as end points. DATA EXTRACTION AND SYNTHESIS: Individual patient data were obtained from randomized clinical trials that met the prespecified eligibility criteria: RACING (Randomized Comparison of Efficacy and Safety of Lipid-Lowering With Statin Monotherapy vs Statin/Ezetimibe Combination for High-Risk Cardiovascular Disease) and LODESTAR (Low-Density Lipoprotein Cholesterol-Targeting Statin Therapy vs Intensity-Based Statin Therapy in Patients With Coronary Artery Disease). The moderate-intensity statin with ezetimibe combination therapy in the RACING trial and the treat-to-target strategy in the LODESTAR trial were classified as alternative LDL cholesterol-lowering strategies. The primary analysis was based on a 1-stage approach. MAIN OUTCOMES AND MEASURES: The primary end point was a 3-year composite of all-cause death, myocardial infarction, stroke, or coronary revascularization. The secondary end points comprised clinical efficacy and safety end points. RESULTS: Individual patient data from 2 trials including 8180 patients with ASCVD (mean [SD] age, 64.5 [9.8] years; 2182 [26.7%] female; 5998 male [73.3%]) were analyzed. The rate of the primary end point did not differ between the alternative strategy and high-intensity statin strategy groups (7.5% [304 of 4094] vs 7.7% [310 of 4086]; hazard ratio, 0.98; 95% CI, 0.84-1.15; P = .82). The mean (SD) LDL cholesterol level during treatment was 64.8 (19.0) mg/dL in the alternative strategy group and 68.5 (20.7) mg/dL in the high-intensity statin strategy group (P < .001). The alternative strategy group had a lower rate of new-onset diabetes (10.2% [271 of 2658] vs 11.9% [316 of 2656]; P = .047), initiation of antidiabetic medication for new-onset diabetes (6.5% [173 of 2658] vs 8.2% [217 of 2656]; P = .02), and intolerance-related discontinuation or dose reduction of assigned therapy (4.0% [163 of 4094] vs 6.7% [273 of 4086]; P < .001). CONCLUSIONS AND RELEVANCE: Results of this systematic review and individual patient data meta-analysis suggest that compared with a high-intensity statin strategy, the alternative LDL cholesterol-lowering strategy demonstrated comparable efficacy regarding 3-year death or cardiovascular events in patients with ASCVD, with an associated reduction in LDL cholesterol levels and risk for new-onset diabetes and intolerance. STUDY REGISTRATION: PROSPERO CRD42024532550.
引用
- Lee YJ, Hong BK, Yun KH, et al. Alternative LDL Cholesterol-Lowering Strategy vs High-Intensity Statins in Atherosclerotic Cardiovascular Disease: A Systematic Review and Individual Patient Data Meta-Analysis. JAMA Cardiol. 2025. PMID: 39565634. doi:10.1001/jamacardio.2024.3911
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。